Joaquim Bellmunt

Joaquim Bellmunt

UNVERIFIED PROFILE

Are you Joaquim Bellmunt?   Register this Author

Register author
Joaquim Bellmunt

Joaquim Bellmunt

Publications by authors named "Joaquim Bellmunt"

Are you Joaquim Bellmunt?   Register this Author

100Publications

3746Reads

35Profile Views

Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome.

Virchows Arch 2019 Oct 23;475(4):457-466. Epub 2019 Apr 23.

Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Passeig Maritim 25-29, 08003, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-019-02573-1DOI Listing
October 2019

Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?

Eur Urol Oncol 2019 Sep 4;2(5):597-602. Epub 2019 Jul 4.

The University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.06.002DOI Listing
September 2019

Does it matter whether a T1 high-grade tumor is molecularly classified?

Eur Urol Oncol 2019 Aug 3. Epub 2019 Aug 3.

Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.07.009DOI Listing
August 2019

Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities.

Nat Rev Urol 2019 Jul;16(7):433-445

Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-019-0183-5DOI Listing
July 2019

Immunotherapy in non-metastatic urothelial cancer: back to the 'future'.

Expert Opin Biol Ther 2019 07 2;19(7):685-695. Epub 2019 May 2.

b Medicine, University Hospital del Mar , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1604673DOI Listing
July 2019

The Cancer Genome Atlas Project in Bladder Cancer.

Cancer Treat Res 2018;175:259-271

Medical Oncology Department, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Hospital del Mar, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-93339-9_12DOI Listing
June 2019

Treatment of Metastatic Urothelial Cancer in 2018.

JAMA Oncol 2019 Jun;5(6):904-905

Medical Oncology Department, Hospital del Mar, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.0182DOI Listing
June 2019

Management of metastatic bladder cancer.

Cancer Treat Rev 2019 Jun 15;76:10-21. Epub 2019 Apr 15.

IMIM-Hospital del Mar Research Institute, Barcelona, Spain; Harvard Medical School, Boston, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2019.04.002DOI Listing
June 2019

Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes.

Clin Cancer Res 2018 12 10;24(24):6115-6124. Epub 2018 Jul 10.

Medical Oncology Department, Hospital del Mar, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-3108DOI Listing
December 2018

Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis.

Qual Life Res 2018 Nov 20;27(11):2759-2775. Epub 2018 Jun 20.

Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-018-1902-8DOI Listing
November 2018

Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.

Eur Urol 2018 11 13;74(5):597-608. Epub 2018 Jul 13.

Division of Urology, Department of Surgery, University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.06.024DOI Listing
November 2018

Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis.

Urol Oncol 2018 10 20;36(10):469.e1-469.e11. Epub 2018 Aug 20.

Vattikuti Urology Institute, Vattikuti Urology Institute (VUI) Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.07.012DOI Listing
October 2018

Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.

Authors:
Joaquim Bellmunt

Biomedicines 2018 Aug 2;6(3). Epub 2018 Aug 2.

Department of Medical Oncology, Hospital del Mar, IMIM (PSMAR-Hospital del Mar Research Institute), 08003 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.mdpi.com/2227-9059/6/3/85
Publisher Site
http://dx.doi.org/10.3390/biomedicines6030085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164884PMC
August 2018

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

J Clin Oncol 2018 06 28;36(16):1579-1587. Epub 2018 Mar 28.

David J. Vaughn, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA; Yves Fradet, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; Jae Lyun Lee, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Republic of Korea; Lawrence Fong, University of California, San Francisco, San Francisco; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Miguel A. Climent, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Daniel P. Petrylak, Smilow Cancer Hospital, Yale University, New Haven, CT; Andrea Necchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan; Cora N. Sternberg, San Camillo and Forlanini Hospitals, Rome, Italy; Winald Gerritsen, Radboud University Medical Center, Nijmegen; Ronald de Wit, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; Howard Gurney, Westmead Hospital and Macquarie University, Sydney, New South Wales, Australia; Stephane Culine, Hôpital Saint-Louis, Paris, France; Yabing Mai, Haojie Li, and Rodolfo F. Perini, Merk & Co., Inc., Kenilworth, NJ; and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.9562
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.9562DOI Listing
June 2018

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.

Eur Urol 2018 05 22;73(5):800-806. Epub 2018 Feb 22.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.02.010DOI Listing
May 2018

Avelumab for the treatment of urothelial cancer.

Expert Rev Anticancer Ther 2018 05 14;18(5):421-429. Epub 2018 Mar 14.

a Medical Oncology Department , Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Hospital del Mar , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1448271DOI Listing
May 2018

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.

Eur Urol Oncol 2018 05 15;1(1):83-90. Epub 2018 May 15.

Center for Outcomes Research, Analytics and Evaluation, Vattikuti Institute of Urology, Henry Ford Hospital, Detroit, MI, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.03.001DOI Listing
May 2018

Comparative effectiveness of robot-assisted vs. open radical cystectomy.

Urol Oncol 2018 03 23;36(3):88.e1-88.e9. Epub 2017 Dec 23.

Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2017.09.018DOI Listing
March 2018

Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma.

Nat Rev Clin Oncol 2018 02 5;15(2):73-74. Epub 2017 Dec 5.

National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.184DOI Listing
February 2018

Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.

Eur Urol 2018 01 3;73(1):40-50. Epub 2017 May 3.

Urology Department, Saint Jean Languedoc Hospital, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.03.019DOI Listing
January 2018

Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.

Clin Genitourin Cancer 2017 12 2;15(6):e1089-e1094. Epub 2017 Aug 2.

Dana-Farber Cancer Institute, Boston, MA; Hospital De Mar Research Institute-IMIM, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.07.012DOI Listing
December 2017

The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review.

Cancer Treat Rev 2017 Dec 6;61:82-93. Epub 2017 Nov 6.

Cancer Research Program, PSMAR-IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader 88, 08003 Barcelona, Spain; Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.10.004DOI Listing
December 2017

ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.

Crit Rev Oncol Hematol 2017 Dec 2;120:120-126. Epub 2017 Nov 2.

Bladder Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428173048
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2017.10.012DOI Listing
December 2017

Pembrolizumab in the treatment of advanced urothelial cancer.

Future Oncol 2017 Dec 12;13(30):2745-2758. Epub 2017 Sep 12.

Dana-Farber Cancer Institute, Department of Genitourinary Oncology, 450 Brookline Ave. Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0284DOI Listing
December 2017

Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.

Cancer 2017 Nov 25;123(22):4346-4355. Epub 2017 Jul 25.

Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30907DOI Listing
November 2017

Antiangiogenesis to curb urothelial cancer.

Authors:
Joaquim Bellmunt

Lancet 2017 11 12;390(10109):2220-2221. Epub 2017 Sep 12.

Dana-Farber Cancer Institute and IMIM-PSMAR Medical Research Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(17)32388-7DOI Listing
November 2017

'Working toward understanding oligo and polymetastatic prostate cancer'.

Curr Opin Urol 2017 11;27(6):532

aMD Anderson Cancer Center, The University of Texas, Houston, Texas bDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000451DOI Listing
November 2017

Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.

Eur Urol 2017 10 12;72(4):483-487. Epub 2017 Apr 12.

Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.03.038DOI Listing
October 2017

Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.

J Urol 2017 10 6;198(4):817-823. Epub 2017 May 6.

Bladder Cancer Center, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2017.04.102DOI Listing
October 2017

Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.

Eur Urol 2017 Aug 9. Epub 2017 Aug 9.

Division of Urologic Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.07.016DOI Listing
August 2017

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

Drugs 2017 Jul;77(10):1077-1089

Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-017-0748-7DOI Listing
July 2017

Pembrolizumab for Advanced Urothelial Carcinoma.

N Engl J Med 2017 06;376(23):2304

Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1704612DOI Listing
June 2017

Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma.

Eur Urol 2017 05 29;71(5):714-718. Epub 2016 Nov 29.

Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.11.012DOI Listing
May 2017

New treatment options for metastatic renal cell carcinoma.

ESMO Open 2017 9;2(2):e000185. Epub 2017 May 9.

Medical Oncology Department, Algemeen Ziekenhuis Klina, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2017-000185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519813PMC
May 2017

Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma.

J Clin Oncol 2017 Mar 3;35(8):852-860. Epub 2017 Jan 3.

Thomas Seisen, Ross E. Krasnow, Jeffrey J. Leow, Stuart R. Lipsitz, Malte W. Vetterlein, Mark A. Preston, Nawar Hanna, Adam S. Kibel, Maxine Sun, Quoc-Dien Trinh, and Steven L. Chang, Brigham and Women's Hospital, Harvard Medical School; Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Morgan Rouprêt, Pitié Salpétrière Hospital, Assistance Publique des Hôpitaux de Paris, Pierre and Marie Curie University, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4141DOI Listing
March 2017

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

N Engl J Med 2017 03 17;376(11):1015-1026. Epub 2017 Feb 17.

From Dana-Farber Cancer Institute, Boston (J.B., T.K.C.); Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona (J.B.), and Fundación Instituto Valenciano de Oncología, Valencia (M.A.C.) - both in Spain; Erasmus MC Cancer Institute, Rotterdam (R.W.), and Radboud University Medical Center, Nijmegen (W.G.) - both in the Netherlands; Abramson Cancer Center, University of Pennsylvania, Philadelphia (D.J.V.); Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, QC, Canada (Y.F.); Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea (J.-L.L.); the University of California, San Francisco, San Francisco (L.F.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Smilow Cancer Hospital, Yale University, New Haven, CT (D.P.P.); Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (A.N.); Westmead Hospital and Macquarie University, Sydney (H.G.); the University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles (D.I.Q.); Hôpital Saint-Louis, Paris (S.C.); San Camillo and Forlanini Hospitals, Rome (C.N.S.); Merck, Kenilworth, NJ (Y.M., C.H.P., R.F.P.); and Memorial Sloan Kettering Cancer Center, New York (D.F.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635424PMC
March 2017

Upper tract urothelial carcinoma: a different disease entity in terms of management.

ESMO Open 2016 24;1(6):e000126. Epub 2017 Jan 24.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://esmoopen.bmj.com/lookup/doi/10.1136/esmoopen-2016-000
Publisher Site
http://dx.doi.org/10.1136/esmoopen-2016-000126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419214PMC
January 2017